The Inherent Risks Of Adopting New Technologies

“Robots don’t fix bad science.” Bringing new technology into your operations always comes with a certain level of risk. In this segment from the Cell & Gene Live event Considerations For Investing In Your Gene Therapy’s Automation Framework, TJ Cradick, Ph.D., CSO of Excision BioTherapeutics, and Matt Humes, head of lab automation at Beam Therapeutics, share stories to illustrate the importance of finding a balance between excitement for new technology and ensuring the foundation of your operations is solid.